Pexidartinib for advanced tenosynovial giant cell tumor: results of the randomized phase 3 ENLIVEN study

BACKGROUND: Tenosynovial giant cell tumor (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy. This phase 3 randomized, double-blind study evaluated pexidartinib, a CSF1 receptor inhibitor, in patients w...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet
Autori principali: Tap, William D., Gelderblom, Hans, Palmerini, Emanuela, Desai, Jayesh, Bauer, Sebastian, Blay, Jean-Yves, Alcindor, Thierry, Ganjoo, Kristen, Martín-Broto, Javier, Ryan, Christopher W., Thomas, David M., Peterfy, Charles, Healey, John H., van de Sande, Michiel, Gelhorn, Heather L., Shuster, Dale E., Wang, Qiang, Yver, Antoine, Hsu, Henry H., Lin, Paul S., Tong-Starksen, Sandra, Stacchiotti, Silvia, Wagner, Andrew J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6860022/
https://ncbi.nlm.nih.gov/pubmed/31229240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(19)30764-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi